Based on RNA-seq data from a subset of our rectal cancer patient population, neither PIK3CA or KRAS mutational status, nor COX-2 mRNA expression were associated with the benefit of aspirin use or tumor downstaging. The gene discussed is KRAS; the disease is rectal cancer.